Sign in
CompletedNo phase

Pre-operative Stereotactic Radiosurgery Followed by Resection for Patients With Brain Metastases

Key facts

Who runs it
Indiana University
Where
Indianapolis, United StatesSee the 3 sites
Trial code
Status
Completed
People taking part
50 people enrolled
Started
26 Mar 2018
Ended
21 May 2024
Type of study
Interventional
Treatments tested
  • Radiosurgery
Record updated
16 July 2024

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 26 criteriaShow less

Who can take part

  • Radiographically confirmed solid tumor brain metastases
  • Criteria for surgical resection of at least one metastasis per neurosurgeon discretion
  • A diagnostic MRI Brain or CT Head demonstrating the presence of 1-4 solid tumor brain metastases and lesion to be resected no more than 5 cm in any direction, performed within 30 days prior to stereotactic radiosurgery. If multiple lesions are present, then the total brain metastases volume can be no more than 30 cm3 excluding the lesion to be resected
  • For known primary included in brainmetgpa.com, an estimated median survival no less than 6 months per brainmetgpa.com
  • For unknown primary or known primary not included within brainmetgpa.com, an estimated median survival no less than 6 months per PI discretion Note: If patient's estimated median survival is calculated using a histology that is different than the histology demonstrated in final pathology, the patient may remain eligible for all study endpoints per PI discretion
  • Surgical candidate per neurosurgeon discretion
  • Surgical resection able to be performed within 1 - 4 days after radiosurgery
  • Stereotactic radiosurgery candidate per radiation oncologist
  • ≥ 18 years old at the time of informed consent
  • Ability to provide written informed consent and HIPAA authorization. This will be assessed by the consenting physician using general questions to determine the patient's ability to understand the medical problem, proposed treatment, alternatives to proposed treatment, and understand the consequences of the medical choices
  • Platelet count > 100 k/cumm, Hgb > 7.5 gm/dL, INR < 1.3, ANC > 1.5 k/cumm
  • Patients currently on cytotoxic chemotherapy or immunotherapy are eligible, not including anti-VEGF therapy
  • If a patient who meets all stated eligibility criteria is enrolled on study and then discovered to be ineligible, the tissue obtained will still be deemed eligible to remain in study for evaluation

Who cannot take part

  • Patients who received anti-VEGF therapy within 6 weeks prior to enrollment, as there is increased risk of fatal brain hemorrhage with surgical resection
  • Previous whole brain radiation therapy
  • Previous radiation therapy to lesion to be resected
  • Planned adjuvant focal therapy including additional radiation therapy to the brain
  • Not a surgical candidate per neurosurgeon's discretion
  • Not a radiosurgical candidate per radiation oncologist's discretion
  • Surgery unable to be performed between 1 - 4 days after radiosurgery
  • Major medical illnesses or psychiatric impairments, which in the investigator's opinion will prevent administration or completion of the protocol therapy and/or interfere with follow-up
  • Total volume of metastatic disease more than 30 cm3 excluding lesion to be resected
  • Patients with more than 4 brain metastases on MRI Brain or CT Head
  • Lesion to be resected is more than 5 cm
  • Patients with leptomeningeal metastases documented by MRI or CSF evaluation
  • Women who are pregnant or nursing are not eligible as treatment involves unforeseeable risks to the fetus or child

Where in United States

  • Indiana University Health HospitalIndianapolis, United States
  • Indiana University Health Methodist HospitalIndianapolis, United States
  • Indiana University Melvin and Bren Simon Comprehensive Cancer CenterIndianapolis, United States

About the trial

What the trial wants to find out

This is a prospective, single arm, phase II trial to determine the local control at 6 months utilizing pre-operative stereotactic radiosurgery followed by surgery within 1 - 4 days in subjects with a diagnosis of 1-4 brain metastases and with an indication for surgical resection of at least one brain metastasis at the discretion of a neurosurgeon.

The group in the trial

  • Arm 1Treatment being tested

    This is a single arm study so this arm will include all eligible subjects. All subjects will have radiosurgery 1-4 days prior to surgical resection.

    Treatment: Radiosurgery

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase II Study Analyzing Pre-operative Stereotactic Radiosurgery Followed by Resection for Patients With 1 - 4 Brain Metastases
Publications
Record updated
16 July 2024